MetLife Investment Advisors LLC reduced its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 10.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,753 shares of the company’s stock after selling 7,700 shares during the period. MetLife Investment Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $1,072,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in TEVA. Two Sigma Advisers LP acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $118,487,000. Franklin Resources Inc. increased its position in shares of Teva Pharmaceutical Industries by 8.2% during the fourth quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock valued at $1,506,309,000 after acquiring an additional 6,009,897 shares during the last quarter. OppenheimerFunds Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $69,418,000. Teachers Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 66.5% during the fourth quarter. Teachers Advisors LLC now owns 3,221,405 shares of the company’s stock valued at $61,046,000 after acquiring an additional 1,286,637 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Teva Pharmaceutical Industries by 56.6% during the fourth quarter. Millennium Management LLC now owns 2,965,936 shares of the company’s stock valued at $56,204,000 after acquiring an additional 1,071,583 shares during the last quarter. Hedge funds and other institutional investors own 65.01% of the company’s stock.
In other news, Director Roberto Mignone purchased 750,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 10th. The stock was bought at an average price of $19.24 per share, for a total transaction of $14,430,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.43% of the stock is owned by insiders.
Shares of Teva Pharmaceutical Industries stock opened at $23.99 on Monday. Teva Pharmaceutical Industries Ltd has a 52-week low of $10.85 and a 52-week high of $33.82. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $24.42 billion, a P/E ratio of 6.10, a PEG ratio of 2.34 and a beta of 0.72.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, May 3rd. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.28. Teva Pharmaceutical Industries had a negative net margin of 72.36% and a positive return on equity of 18.59%. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.80 billion. During the same quarter in the previous year, the firm earned $1.06 earnings per share. The firm’s quarterly revenue was down 10.0% on a year-over-year basis. equities research analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.57 EPS for the current fiscal year.
TEVA has been the subject of a number of recent analyst reports. Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, March 1st. Vetr cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $21.73 price target for the company. in a research report on Monday, March 12th. Jefferies Financial Group initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, March 20th. They set a “hold” rating and a $19.00 price target for the company. Royal Bank of Canada reiterated a “hold” rating and set a $16.00 price target on shares of Teva Pharmaceutical Industries in a research report on Monday, March 26th. Finally, ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 2nd. Nine investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $19.90.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.